Skin Cancer Diagnostic Market Size to Hit USD 13.96 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Skin Cancer Diagnostic Market

5.1. COVID-19 Landscape: Skin Cancer Diagnostic Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Skin Cancer Diagnostic Market, By Type of Cancer

8.1. Skin Cancer Diagnostic Market, by Type of Cancer

8.1.1. Melanoma

8.1.1.1. Market Revenue and Forecast

8.1.2. Basal Cell Carcinoma

8.1.2.1. Market Revenue and Forecast

8.1.3. Squamous Cell Carcinoma

8.1.3.1. Market Revenue and Forecast

8.1.4. Others

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Skin Cancer Diagnostic Market, By Diagnostic Test/Technique

9.1. Skin Cancer Diagnostic Market, by Diagnostic Test/Technique

9.1.1. Visual Examination & Dermoscopy

9.1.1.1. Market Revenue and Forecast

9.1.2. Biopsy

9.1.2.1. Market Revenue and Forecast

9.1.3. Imaging Tests

9.1.3.1. Market Revenue and Forecast

9.1.4. Molecular & Genetic Tests

9.1.4.1. Market Revenue and Forecast

9.1.5. Others

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Skin Cancer Diagnostic Market, By Diagnostic Tool/Device

10.1. Skin Cancer Diagnostic Market, by Diagnostic Tool/Device

10.1.1. Dermatoscopes

10.1.1.1. Market Revenue and Forecast

10.1.2. Imaging Systems

10.1.2.1. Market Revenue and Forecast

10.1.3. Biopsy Instruments

10.1.3.1. Market Revenue and Forecast

10.1.4. Molecular Diagnostic Kits

10.1.4.1. Market Revenue and Forecast

10.1.5. AI & Tele-dermatology Platforms

10.1.5.1. Market Revenue and Forecast

Chapter 11. Global Skin Cancer Diagnostic Market, By End User

11.1. Skin Cancer Diagnostic Market, by End User

11.1.1. Hospitals & Cancer Centers (Dominant ~42%)

11.1.1.1. Market Revenue and Forecast

11.1.2. Dermatology Clinics (~28%)

11.1.2.1. Market Revenue and Forecast

11.1.3. Diagnostic Laboratories (~21%)

11.1.3.1. Market Revenue and Forecast

11.1.4. Ambulatory Surgical Centers

11.1.4.1. Market Revenue and Forecast

11.1.5. Home-based & Tele-dermatology Platforms

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global Skin Cancer Diagnostic Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Type of Cancer

12.1.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.1.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.1.4. Market Revenue and Forecast, by End User

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Type of Cancer

12.1.5.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.1.5.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.1.5.4. Market Revenue and Forecast, by End User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Type of Cancer

12.1.6.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.1.6.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.1.6.4. Market Revenue and Forecast, by End User

12.2. Europe

12.2.1. Market Revenue and Forecast, by Type of Cancer

12.2.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.2.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.2.4. Market Revenue and Forecast, by End User

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Type of Cancer

12.2.5.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.2.5.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.2.5.4. Market Revenue and Forecast, by End User

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Type of Cancer

12.2.6.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.2.6.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.2.6.4. Market Revenue and Forecast, by End User

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Type of Cancer

12.2.7.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.2.7.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.2.7.4. Market Revenue and Forecast, by End User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Type of Cancer

12.2.8.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.2.8.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.2.8.4. Market Revenue and Forecast, by End User

12.3. APAC

12.3.1. Market Revenue and Forecast, by Type of Cancer

12.3.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.3.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.3.4. Market Revenue and Forecast, by End User

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Type of Cancer

12.3.5.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.3.5.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.3.5.4. Market Revenue and Forecast, by End User

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Type of Cancer

12.3.6.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.3.6.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.3.6.4. Market Revenue and Forecast, by End User

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Type of Cancer

12.3.7.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.3.7.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.3.7.4. Market Revenue and Forecast, by End User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Type of Cancer

12.3.8.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.3.8.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.3.8.4. Market Revenue and Forecast, by End User

12.4. MEA

12.4.1. Market Revenue and Forecast, by Type of Cancer

12.4.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.4.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.4.4. Market Revenue and Forecast, by End User

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Type of Cancer

12.4.5.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.4.5.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.4.5.4. Market Revenue and Forecast, by End User

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Type of Cancer

12.4.6.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.4.6.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.4.6.4. Market Revenue and Forecast, by End User

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Type of Cancer

12.4.7.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.4.7.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.4.7.4. Market Revenue and Forecast, by End User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Type of Cancer

12.4.8.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.4.8.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.4.8.4. Market Revenue and Forecast, by End User

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Type of Cancer

12.5.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.5.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.5.4. Market Revenue and Forecast, by End User

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Type of Cancer

12.5.5.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.5.5.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.5.5.4. Market Revenue and Forecast, by End User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Type of Cancer

12.5.6.2. Market Revenue and Forecast, by Diagnostic Test/Technique

12.5.6.3. Market Revenue and Forecast, by Diagnostic Tool/Device

12.5.6.4. Market Revenue and Forecast, by End User

Chapter 13. Company Profiles

13.1. F. Hoffmann-La Roche Ltd.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Abbott Laboratories

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Siemens Healthineers

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Philips Healthcare

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Leica Biosystems (Danaher)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Agilent Technologies

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Illumina Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. DermLite

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. FotoFinder Systems GmbH

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Heine Optotechnik

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The skin cancer diagnostic market size is expected to increase from USD 8.54 billion in 2024 to USD 13.96 billion by 2034.

The skin cancer diagnostic market is expected to grow at a compound annual growth rate (CAGR) of around 5.04% from 2025 to 2034.

The major players in the skin cancer diagnostic market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers, Philips Healthcare, Leica Biosystems (Danaher), Agilent Technologies, Illumina Inc., DermLite, FotoFinder Systems GmbH, Heine Optotechnik, Verisante Technology, Strata Skin Sciences, Caliber Imaging & Diagnostics, DermTech Inc., Myriad Genetics, Castle Biosciences, SkinVision, Canfield Scientific, 3Gen Inc., and Novartis (dermatology collaborations.

The driving factors of the skin cancer diagnostic market are the rising global incidence of skin cancer, increasing awareness of early detection, advancements in diagnostic technologies, and growing adoption of AI-based imaging tools.

North America region will lead the global skin cancer diagnostic market during the forecast period 2025 to 2034.